G Chen, Y Zhang, Y Zhou, H Luo… - Journal of Inflammation …, 2024 - Taylor & Francis
Despite advancements in cancer treatment through surgery and drugs, hepatocellular carcinoma (HCC) remains a significant challenge, as reflected by its low survival rates. The …
Q Xia, J Xie, J Zhang, L Zhang, Y Zhou, B Zhu… - Chemico-Biological …, 2024 - Elsevier
Ovatodiolide is a macrocyclic diterpenoid compound with various biological activities that displays considerable anticancer potential in different tumor models. However, the …
SE Diab, NA Tayea, BH Elwakil, SS Elshewemi… - Scientific Reports, 2024 - nature.com
The present work aimed to assess the potential effect of sericin/propolis/fluorouracil nanoformula against colorectal cancer (CRC)(the fourth most common cause of cancer …
C Xu, S Wen, X Du, X Zou, ELH Leung, G Zhou… - Pharmacological …, 2024 - Elsevier
Regulated cell death (RCD) is a type of cell death modulated by specific signal transduction pathways. Currently, known RCD types include apoptosis, autophagy, ferroptosis …
MS Hsieh, MY Chen, YS Chang, CS Huang, TN Hsu… - Life Sciences, 2024 - Elsevier
The discovery of SARS-CoV-2 RNA in the periodontal tissues of patients who tested positive for COVID-19, 24 days post the initial symptom onset, indicates the oral cavity could serve as …
CY Chen, YZ Ye, YH Huang, YM Tzeng… - Chemico-Biological …, 2024 - Elsevier
Endometrial cancer (EC) is a common gynecological cancer worldwide, often associated with a poor prognosis after recurrence or metastasis. Ovatodiolide (OVA) is a macrocyclic …
W Luo, J Zhou, Y Yan, X Xu - Genes & Diseases, 2025 - Elsevier
Ribosome biogenesis is a multi-step process that initiates within the nucleolus, terminates in the cytoplasm, and determines the rate of protein synthesis. Ribosome biogenesis is …
Until recently, sorafenib has been the only treatment approved by the US Food and Drug Administration for patients with advanced hepatocellular carcinoma (HCC). Some patients …
Z Tan, X Li, X Chen, L Wang, B Chen, S Ren, M Zhao - Heliyon, 2024 - cell.com
Background Sorafenib is a classic molecular targeted drug approved for hepatocellular carcinoma (HCC) therapy. However, a poor response rate and increasing resistance to …